Correspondence 0001213900-24-112607 from ADIAL PHARMACEUTICALS, INC. (ADIL)
ADIAL PHARMACEUTICALS, INC.
Date: Dec. 26, 2024 · CIK: 0001513525 · Accession: 0001213900-24-112607
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-283968
Letter
VIA EDGAR United States Securities Division of Corporation Finance Attention: Daniel Crawford Re: Adial Pharmaceuticals, Inc. Registration Statement on Form S-1 Filed December 20, 2024 File No: 333-283968
Dear Mr. Crawford:
Adial Pharmaceuticals, Inc. (the “Registrant”) hereby requests that the effective date of the above-referenced Registration Statement on Form S-1 (File No. 333-283968), be accelerated by the U.S. Securities and Exchange Commission (the “Commission”) to become effective on Monday, December 30, 2024, at 4:00 p.m., Eastern Time, or as soon as reasonably practicable thereafter.
The Registrant understands that the Staff of the Commission will consider this request as confirmation by the Registrant that it is aware of its responsibilities under the federal securities laws as they relate to the issuance of the securities covered by the Registration Statement.
The Registrant hereby authorizes Leslie Marlow and/or Hank Gracin of Blank Rome LLP to orally modify or withdraw this request for acceleration. Please contact Ms. Marlow at (516) 457-4238, or Mr. Gracin at (561) 926-7995 with any questions you may have concerning this request, and please notify either of them when this request for acceleration has been granted.
Very truly yours,
ADIAL PHARMACEUITCALS, INC.
Show Raw Text
CORRESP
1
filename1.htm
December 26, 2024
VIA EDGAR
United States Securities
and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Attention: Daniel Crawford
Re:
Adial Pharmaceuticals, Inc.
Registration Statement on Form S-1
Filed December 20, 2024
File No: 333-283968
Dear Mr. Crawford:
Adial Pharmaceuticals, Inc.
(the “Registrant”) hereby requests that the effective date of the above-referenced Registration Statement on Form S-1
(File No. 333-283968), be accelerated by the U.S. Securities and Exchange Commission (the “Commission”) to become effective
on Monday, December 30, 2024, at 4:00 p.m., Eastern Time, or as soon as reasonably practicable thereafter.
The Registrant understands
that the Staff of the Commission will consider this request as confirmation by the Registrant that it is aware of its responsibilities
under the federal securities laws as they relate to the issuance of the securities covered by the Registration Statement.
The Registrant hereby authorizes
Leslie Marlow and/or Hank Gracin of Blank Rome LLP to orally modify or withdraw this request for acceleration. Please contact Ms. Marlow
at (516) 457-4238, or Mr. Gracin at (561) 926-7995 with any questions you may have concerning this request, and please notify either of
them when this request for acceleration has been granted.
Very truly yours,
ADIAL PHARMACEUITCALS, INC.
By:
/s/ Cary Claiborne
Name:
Cary Claiborne
Title:
Chief Executive Officer
cc: Leslie Marlow, Blank Rome LLP
Hank Gracin, Blank Rome LLP